4//SEC Filing
NEA 14 GP, LTD 4
Accession 0001209191-18-050279
CIK 0001621227other
Filed
Sep 9, 8:00 PM ET
Accepted
Sep 10, 4:45 PM ET
Size
9.5 KB
Accession
0001209191-18-050279
Insider Transaction Report
Form 4
NEA Partners 14, L.P.
10% Owner
Transactions
- Purchase
Ordinary Shares with a nominal value of 0.001 GBP per share
2018-09-07$1.67/sh+3,000,000$5,000,100→ 82,978,668 total
New Enterprise Associates 14, L.P.
10% Owner
Transactions
- Purchase
Ordinary Shares with a nominal value of 0.001 GBP per share
2018-09-07$1.67/sh+3,000,000$5,000,100→ 82,978,668 total
NEA 14 GP, LTD
10% Owner
Transactions
- Purchase
Ordinary Shares with a nominal value of 0.001 GBP per share
2018-09-07$1.67/sh+3,000,000$5,000,100→ 82,978,668 total
Footnotes (3)
- [F1]The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.
- [F2]The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six.
- [F3]The securities are directly held by NEA 14 and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell, Peter W. Sonsini and Ravi Viswanathan. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.
Documents
Issuer
Adaptimmune Therapeutics PLC
CIK 0001621227
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001551532
Filing Metadata
- Form type
- 4
- Filed
- Sep 9, 8:00 PM ET
- Accepted
- Sep 10, 4:45 PM ET
- Size
- 9.5 KB